NCT00544466View on ClinicalTrials.gov

Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

August 1, 2013

Study Completion Date

December 16, 2025

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

fludarabine phosphate

25 mg/m2 day -7 through day -3 prior to transplant

DRUG

melphalan

140 mg/m2 day -2 prior to transplant

PROCEDURE

allogeneic hematopoietic stem cell transplantation

Cells infused on Day 0 of transplant regimen

RADIATION

intensity-modulated radiation therapy

Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant

Trial Locations (1)

91010-3000

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER